Calcimimetics and Bundled Reimbursement

Eugene Lin, Suzanne Watnick

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since 2011, the Centers for Medicare & Medicaid Services has provided reimbursement for renal dialysis services furnished to Medicare beneficiaries through a bundled payment system known as the Prospective Payment System. Medications that have no injectable equivalent, known as “oral-only medications,” are currently excluded from the bundle and are paid separately through Medicare Part D. Thus, before the development of etelcalcetide, the first injectable calcimimetic, calcimimetics were reimbursed outside the bundle. Etelcalcetide's introduction and approval for use in Medicare triggered a transition payment for a minimum of 2 years that will eventually result in the incorporation of calcimimetics into the dialysis bundle. Consequently, providers may face incentives to reduce calcimimetic use when the transition period has expired. The complexity of bone-mineral management in conjunction with the paucity of evidence-based recommendations in this area makes it difficult to predict the impact of this transition. Because these medications are expensive, a poor transition could have financial ramifications for dialysis organizations and potentially patient health. To ensure that patients are not adversely affected, it is critical that Medicare incorporate these medications into the bundle carefully, with close monitoring of outcomes.

Original languageEnglish (US)
Pages (from-to)385-390
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume73
Issue number3
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Medicare
Dialysis
Medicare Part D
Prospective Payment System
Injections
Medicaid
Minerals
Renal Dialysis
Motivation
Organizations
Bone and Bones
Health

Keywords

  • bone-mineral metabolism
  • bundle
  • calcimimetic
  • dialysis clinic
  • drug costs
  • end-stage renal disease (ESRD)
  • Etelcalcetide
  • health care incentive
  • hemodialysis
  • medical parathyroidectomy
  • parathyroid hormone (PTH)
  • payment
  • Prospective Payment System (PPS)
  • reimbursement rate
  • transition

ASJC Scopus subject areas

  • Nephrology

Cite this

Calcimimetics and Bundled Reimbursement. / Lin, Eugene; Watnick, Suzanne.

In: American Journal of Kidney Diseases, Vol. 73, No. 3, 01.03.2019, p. 385-390.

Research output: Contribution to journalArticle

Lin, Eugene ; Watnick, Suzanne. / Calcimimetics and Bundled Reimbursement. In: American Journal of Kidney Diseases. 2019 ; Vol. 73, No. 3. pp. 385-390.
@article{b090209bd3c2488faf441d7b7110b723,
title = "Calcimimetics and Bundled Reimbursement",
abstract = "Since 2011, the Centers for Medicare & Medicaid Services has provided reimbursement for renal dialysis services furnished to Medicare beneficiaries through a bundled payment system known as the Prospective Payment System. Medications that have no injectable equivalent, known as “oral-only medications,” are currently excluded from the bundle and are paid separately through Medicare Part D. Thus, before the development of etelcalcetide, the first injectable calcimimetic, calcimimetics were reimbursed outside the bundle. Etelcalcetide's introduction and approval for use in Medicare triggered a transition payment for a minimum of 2 years that will eventually result in the incorporation of calcimimetics into the dialysis bundle. Consequently, providers may face incentives to reduce calcimimetic use when the transition period has expired. The complexity of bone-mineral management in conjunction with the paucity of evidence-based recommendations in this area makes it difficult to predict the impact of this transition. Because these medications are expensive, a poor transition could have financial ramifications for dialysis organizations and potentially patient health. To ensure that patients are not adversely affected, it is critical that Medicare incorporate these medications into the bundle carefully, with close monitoring of outcomes.",
keywords = "bone-mineral metabolism, bundle, calcimimetic, dialysis clinic, drug costs, end-stage renal disease (ESRD), Etelcalcetide, health care incentive, hemodialysis, medical parathyroidectomy, parathyroid hormone (PTH), payment, Prospective Payment System (PPS), reimbursement rate, transition",
author = "Eugene Lin and Suzanne Watnick",
year = "2019",
month = "3",
day = "1",
doi = "10.1053/j.ajkd.2018.11.007",
language = "English (US)",
volume = "73",
pages = "385--390",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Calcimimetics and Bundled Reimbursement

AU - Lin, Eugene

AU - Watnick, Suzanne

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Since 2011, the Centers for Medicare & Medicaid Services has provided reimbursement for renal dialysis services furnished to Medicare beneficiaries through a bundled payment system known as the Prospective Payment System. Medications that have no injectable equivalent, known as “oral-only medications,” are currently excluded from the bundle and are paid separately through Medicare Part D. Thus, before the development of etelcalcetide, the first injectable calcimimetic, calcimimetics were reimbursed outside the bundle. Etelcalcetide's introduction and approval for use in Medicare triggered a transition payment for a minimum of 2 years that will eventually result in the incorporation of calcimimetics into the dialysis bundle. Consequently, providers may face incentives to reduce calcimimetic use when the transition period has expired. The complexity of bone-mineral management in conjunction with the paucity of evidence-based recommendations in this area makes it difficult to predict the impact of this transition. Because these medications are expensive, a poor transition could have financial ramifications for dialysis organizations and potentially patient health. To ensure that patients are not adversely affected, it is critical that Medicare incorporate these medications into the bundle carefully, with close monitoring of outcomes.

AB - Since 2011, the Centers for Medicare & Medicaid Services has provided reimbursement for renal dialysis services furnished to Medicare beneficiaries through a bundled payment system known as the Prospective Payment System. Medications that have no injectable equivalent, known as “oral-only medications,” are currently excluded from the bundle and are paid separately through Medicare Part D. Thus, before the development of etelcalcetide, the first injectable calcimimetic, calcimimetics were reimbursed outside the bundle. Etelcalcetide's introduction and approval for use in Medicare triggered a transition payment for a minimum of 2 years that will eventually result in the incorporation of calcimimetics into the dialysis bundle. Consequently, providers may face incentives to reduce calcimimetic use when the transition period has expired. The complexity of bone-mineral management in conjunction with the paucity of evidence-based recommendations in this area makes it difficult to predict the impact of this transition. Because these medications are expensive, a poor transition could have financial ramifications for dialysis organizations and potentially patient health. To ensure that patients are not adversely affected, it is critical that Medicare incorporate these medications into the bundle carefully, with close monitoring of outcomes.

KW - bone-mineral metabolism

KW - bundle

KW - calcimimetic

KW - dialysis clinic

KW - drug costs

KW - end-stage renal disease (ESRD)

KW - Etelcalcetide

KW - health care incentive

KW - hemodialysis

KW - medical parathyroidectomy

KW - parathyroid hormone (PTH)

KW - payment

KW - Prospective Payment System (PPS)

KW - reimbursement rate

KW - transition

UR - http://www.scopus.com/inward/record.url?scp=85059342054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059342054&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2018.11.007

DO - 10.1053/j.ajkd.2018.11.007

M3 - Article

VL - 73

SP - 385

EP - 390

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -